Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Patent CN118480524B details mutant enzyme synthesis for chloramphenicol intermediates. Delivers high yield and green manufacturing advantages for reliable pharmaceutical intermediates supplier partnerships.
Novel nickel catalyzed method enables room temperature synthesis of high purity chiral trifluoromethyl compounds offering significant supply chain and cost advantages for pharmaceutical intermediates manufacturing.
Patent CN114277073A reveals gene-knockout method for high-purity SAM. Reduces purification costs and ensures supply chain stability for pharmaceutical intermediates.
Novel enzymatic route for tofacitinib intermediate offers high purity and yield. Reduces cost and waste for pharmaceutical manufacturing supply chains.
Patent CN106795198B enables high yield synthesis. Reduces costs and improves supply chain reliability for oncology intermediate manufacturing globally.
Patent CN116179503A details a novel recombinant aminotransferase route for Niraparib intermediates, offering high stereoselectivity and eliminating costly chiral chromatography for supply chain efficiency.
Patent CN112110868A reveals a novel crystalline intermediate route for Fmoc-beta-Ala-AA-OH, offering significant cost reduction in pharmaceutical manufacturing and enhanced supply chain reliability.
Patent CN1101817C reveals a cost-effective route to tetraazamacrocycles using dichloroethane and halide catalysts, offering significant supply chain advantages for MRI contrast agent precursors.
Patent CN111925330A reveals a high-yield Altimezole preparation method eliminating palladium catalysts, offering cost reduction and scalable veterinary intermediate manufacturing.
Novel synthesis route for PARP inhibitor intermediates offers significant cost reduction and supply chain reliability for global pharmaceutical manufacturing partners.
Patent CN1343203A details a novel scalable route for 1,4,7,10-tetraazacyclododecane, offering cost reduction in MRI contrast agent manufacturing through improved salt isolation.
Patent CN104561142A reveals nitrilase biosynthesis for statin intermediates. Offers mild conditions, high yield, and supply chain stability for global pharmaceutical manufacturing.
Patent CN114150009A reveals a novel enzymatic route for ephedrine using engineered E. coli and yeast, offering high yield and environmental compliance for pharma supply chains.
Patent CN120865012A reveals high-purity synthesis for diatrizoic acid impurity D, ensuring supply chain reliability and cost reduction in pharmaceutical manufacturing.
Patent CN112175892B reveals a novel co-expression engineering bacterium reducing PLP dependency. Discover cost-effective antibiotic intermediate manufacturing solutions.
Patent CN103014081A details a green enzymatic route for 3-amino-4-(2,4,5-trifluorophenyl)methyl butyrate, offering superior chirality and cost reduction in pharmaceutical intermediate manufacturing.
High-yield imine reductase method for ephedrine production offers supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN116926574A reveals a green electrochemical method for spirocyclic indoles, eliminating metal catalysts and oxidants for cost-effective pharmaceutical intermediate manufacturing.
Novel synthesis route for 2-deoxy-D-glucose via glucosamine. Reduces cost and complexity. Ideal for API manufacturing scale-up and high-purity production.
Patent CN105130924A offers high-yield synthesis for Febuxostat intermediate. Achieve 99% purity with reduced costs and scalable pharmaceutical intermediate production processes.